|
|
||||||||
J Thorac Cardiovasc Surg 2000;120:428
© 2000 The American Association for Thoracic Surgery
Letters to the editor |
Consultant Cardiothoracic Surgeon
Sir Charles Gairdner Hospital Perth, 6009 West Australia
Reply to the editor:
I thank the team from the German Heart Center in Munich for informing our surgical readership of the impressive and certainly novel use of C1 esterase inhibitor protein in cases of severe myocardial dysfunction after a percutaneous revascularization procedure. I presume that, in addition to the use of cardiopulmonary bypass, inotropic dilators, catecholamines, and balloon counterpulsation, these patients having percutaneous procedures for coronary disease actually had emergency coronary bypass grafting too! Certainly it is these patients requiring emergency bypass with profound preoperative left ventricular dysfunction who are widely recognized as having the highest operative mortality.
1 Therefore, given the results published by Bauernschmitt and colleagues, the use of C1 esterase inhibitor protein merits investigation by surgeons faced with these ever-increasing groups of patients.
12/8/107822 doi:10.1067/mtc.2000.107822
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |